MSB 0.51% 97.0¢ mesoblast limited

Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-438

  1. 16,879 Posts.
    lightbulb Created with Sketch. 2402
    Really Col... You need to read the text a bit more carefully

    “We are very pleased with FDA’s feedback that the presented results from our pivotal study of rexlemestrocel-L in end-stage HFrEF patients with LVADs MAY support an accelerated approval,” said Mesoblast CEO Dr. Silviu Itescu. “We intend to request a pre-Biologics License Application (BLA) meeting to discuss data presentation, timing and FDA expectations for an accelerated approval filing.”
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
-0.005(0.51%)
Mkt cap ! $1.107B
Open High Low Value Volume
98.5¢ 98.5¢ 96.0¢ $2.168M 2.226M

Buyers (Bids)

No. Vol. Price($)
1 16000 96.5¢
 

Sellers (Offers)

Price($) Vol. No.
97.0¢ 86854 7
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.